Anfibatide Phase 1 Clinical Trial in Healthy Volunteers
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
In this 94 healthy subjects Phase I clinical trial, we assess the clinical profile of
Anfibatide, a specific glycoprotein Ib antagonist. This study represents the first clinical
evidence that Anfibatide exhibits strong anti-platelet effects, excellent reversibility, and
low bleeding potential in healthy human subjects.